In 1987, Kay et al published the Positive and Negative Syndrome Scale (PANSS) and the PANSS manual to address the limitations of existing instruments for schizophrenia research. The PANSS has been one of the most widely used instruments in schizophrenia research—until now. Because of recent advances in neuroscience research, it has become essential to reevaluate the performance of the PANSS since its development 3 decades ago.
Methods
A comprehensive literature review of the PANSS from 1987 to 2015 using a PubMed search was conducted.
Results
Five drawbacks to the PANSS have been cited in the literature. Although several authors have pointed out flaws of the PANSS, no revisions or modifications have been attempted to address them. In addition, some researchers do not use the PANSS as intended by the authors, and other researchers misuse it.
Conclusions
The PANSS is a reliable and valid instrument that has served the scientific research community well for decades. New advances in experimental psychopathology and personalized psychiatry and the new National Institute of Mental Health paradigm of Research Domain Criteria necessitate a new instrument compatible with advances in clinical neuroscience research.
Get full access to this article
View all access options for this article.
References
1.
KaySR, FiszbeinA, OplerLA.The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
2.
KaySR, FiszbeinA, OplerLA.The positive and negative syndrome scale (PANSS) rating manual. San Rafael, CA: Social and Behavioral Sciences Documents;1987.
3.
OplerLA, RamirezPM.Structured Clinical Interview for the PANSS (SCI-PANSS). Toronto, Ontario, Canada: Multi-Health Systems;1992.
4.
SpitzerRL, WilliamsJB, GibbonM, . The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry.1992;49:624–629.
5.
KaySR, OplerLA, SpitzerRL, . SCID-PANSS: two-tier diagnostic system for psychotic disorders. Compr Psychiatry. 1991;32:355–361.
6.
KaySR, OplerLA, LindenmayerJP.Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988;23:99–110.
7.
NicotraE, CasuG, PirasS, . On the use of the Positive and Negative Syndrome Scale in randomized clinical trials. Schizophr Res. 2015;165:181–187.
8.
ObermeierM, MayrA, Schennach-WolffR, . Should the PANSS be rescaled? Schizophr Bull. 2010;36:455–460.
9.
NasrallahHA, TandonR.Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry. 2002;63:(suppl 13)12–20.
10.
AndreasenNC, OlsenS.Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry. 1982;39:789–794.
11.
CrowTJ.Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry. 1980;137:383–386.
12.
PeraltaV, CuestaMJ.Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res. 1994;53:31–40.
13.
AndersonA, WilcoxM, SavitzA, . Sparse factors for the positive and negative syndrome scale: which symptoms and stage of illness? Psychiatry Res. 2015;225:283–290.
14.
XuK, KrystalJH, NingY, . Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. J Psychiatr Res. 2015;61:64–72.
15.
Villalta-GilV, VilaplanaM, OchoaS, . Four symptom dimensions in outpatients with schizophrenia. Compr Psychiatry. 2006;47:384–388.
16.
LindenmayerJP, Bernstein-HymanR, GrochowskiS.A new five factor model of schizophrenia. Psychiatr Q. 1994;65:299–322.
17.
MarderSR, DavisJM, ChouinardG.The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538–546.
18.
Van den OordEJ, RujescuD, RoblesJR, . Factor structure and external validity of the PANSS revisited. Schizophr Res. 2006;82:213–223.
19.
KaneJM, SanchezR, PerryPP, . Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73:617–624.
20.
BurrisKD, MolskiTF, XuC, . Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381–389.
21.
ShapiroDA, RenockS, ArringtonE, . Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol. 2003;28:1400–1411.
22.
BestMW, GrossmanM, OyewumiLK, . Examination of the Positive and Negative Syndrome Scale factor structure and longitudinal relationships with functioning in early psychosis [published online October 2, 2014]. Early Interv Psychiatry. doi: 10.1111/eip.12190.
23.
JelastopuluE, GiourouE, MerekouliasG, . Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia. BMC Psychiatry. 2014;14:197.
24.
ChaichanW.Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p. r.n. medication. J Psychiatr Pract.2008;14:105–113.
25.
WoodwardTS, JungK, SmithGN, . Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis. Eur Arch Psychiatry Clin Neurosci. 2014;264:673–682.
26.
LindenmayerJ P, BossieCA, KujawaM, . Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale. Psychopathology. 2008;41:264–270.
27.
StefanovicsEA, KrystalJH, RosenheckRA.Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia. Compr Psychiatry. 2014;55:887–895.
28.
PadmanabhanJL, TandonN, HallerCS, . Correlations between brain structure and symptom dimensions of psychosis in schizophrenia, schizoaffective, and psychotic bipolar I disorders. Schizophr Bull. 2015;41:154–162.
29.
Oertel-KnöchelV, KnöchelC, Rotarska-JagielaA, . Association between psychotic symptoms and cortical thickness reduction across the schizophrenia spectrum. Cereb Cortex. 2013;23:61–70.
30.
SharafiM.Comparison of classical and clozapine treatment on schizophrenia using Positive and Negative Syndrome Scale of schizophrenia (PANSS) and SPECT imaging. Int J Med Sci. 2005;2:79–86.
31.
MoritzS, VeckenstedtR, AndreouC, . Sustained and “sleeper” effects of group metacognitive training for schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2014;71:1103–1111.
32.
NasrallahHA, SilvaR, PhillipsD, . Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47:670–677.
33.
LevineSZ, RabinowitzJ, RizopoulosD.Recommendations to improve the positive and negative syndrome scale (PANSS) based on item response theory. Psychiatry Res. 2011;188:446–452.
34.
NasrallahHA.Long overdue: measurement-based psychiatric practice. Current Psychiatry. 2009;8:14–16.
35.
LeuchtS, KisslingW, DavisJM.The PANSS should be rescaled. Schizophr Bull. 2010;36:461–462.
36.
MooreD P, PuriBK.Textbook of clinical neuropsychiatry and behavioral neuroscience. 3rd ed.Boca Raton, FL: CRC Press;2012.
37.
AggernaesA.The experienced reality of hallucinations and other psychological phenomena. An empirical analysis. Acta Psychiatr Scand.1972;48:220–238.
38.
AndreasenNC, CarpenterWTJr, KaneJM, . Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
39.
SheehanDV, LecrubierY, SheehanKH, . The Mini-International Neuropsychiatric Interview (M. I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry.1998;59:(suppl 20)22–33; quiz 34-57.
40.
HaddockG, McCarronJ, TarrierN, . Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med. 1999;29:879–889.
41.
PigottTA, CarsonWH, SahaAR, ; Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry.2003;64:1048–1056.
42.
BerwaertsJ, LiuY, GopalS, . Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72:830-839.
43.
FleischhackerWW, McQuadeRD, MarcusRN, . A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009;65:510–517.
LasserRA, BossieCA, GharabawiGM, . Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res. 2005;77:215–227.
46.
BartaPE, PearlsonGD, PowersRE, . Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry. 1990;147:1457-1462.
47.
PalaniyappanL, BalainV, RaduaJ, . Structural correlates of auditory hallucinations in schizophrenia: a meta-analysis. Schizophr Res. 2012;137:169–173.
48.
JardriR, PouchetA, PinsD, . Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. Am J Psychiatry. 2011;168:73–81.
49.
ShentonME, KikinisR, JoleszFA, . Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N Engl J Med. 1992;327:604–612.
50.
AborayaA, NasrallahH, MuvvalaS, . The Standard for Clinicians’ Interview in Psychiatry (SCIP): a clinician-administered tool with categorical, dimensional and numeric output. Conceptual development, design and description of the SCIP.Innov Clin Neurosci. In press.
51.
OzomaroU, WahlestedtC, NemeroffCB.Personalized medicine in psychiatry: problems and promises. BMC Med. 2013;11:132.
52.
AndreasenNC, FlaumM.Schizophrenia: the characteristic symptoms. Schizophr Bull. 1991;17:27-49.
53.
AborayaA.The validity results of the Standard for Clinicians’ Interview in Psychiatry (SCIP). Schizophr Bull.2015;41:S103–S104.
54.
AborayaA, El-MissiryA, BarloweJ, . The reliability of the Standard for Clinicians’ Interview in Psychiatry (SCIP): a clinician-administered tool with categorical, dimensional and numeric output. Schizophr Res. 2014;156:174–183.
